Exclusive to every day finance, pay attention quickly
On the last trading day of April, the synthetic biology concept performed strongly. In the Straight Flush concept section, the concept of synthetic biology ranks first in popularity. As of the close of the day, the "20CM" daily limit of Chuanning Biotechnology, Yiduoli, Fujilai, Lukang Pharmaceutical, Shengda Biotechnology, Weilan Biotechnology, etc.
A few days ago, Tan Tianwei, president of Beijing University of Chemical Technology and academician of the Chinese Academy of Engineering, said that the bioeconomy is expected to become the fourth industrial revolution in the future after the agricultural revolution, industrial revolution and digital revolution. Led by the National Development and Reform Commission, the Ministry of Industry and Information Technology and the Ministry of Science and Technology and other national ministries and commissions are jointly developing a national biotechnology and biomanufacturing action plan, and it is expected to be introduced in the near future, "biomanufacturing +" is the key content. With the further breakthrough progress of biotechnology, biomanufacturing is also expected to expand to mining, metallurgy, electronic information, environmental protection and other fields, and the development prospects are very broad, becoming an important engine of economic growth.
Q
What is Synthetic Biology?
A
According to public information, synthetic biology is an emerging discipline based on engineering design concepts, combined with interdisciplinary technologies such as biology, chemistry, medicine, agronomy, engineering, computer and data science, using renewable biomass as raw materials and organisms as production media, aiming to use cheap raw materials to transform or create artificial life systems. Since its advent at the beginning of the 21st century, synthetic biology has undergone technological breakthroughs in multiple directions such as DNA engineering, biomolecular engineering, host engineering, and computer technology, and has developed into a highly systematic discipline.
Q
What are the advantages of synthetic biology?
A
Synthetic biology is clean, efficient, and renewable, and has the potential to completely subvert the existing pattern at both the level of science and technology and industrial innovation.
Q
How is the synthetic biology industry chain distributed?
A
Upstream: Focus on the development of enabling technologies, including read-write-editing-learning, automation, high-pass quantification, and biomanufacturing, and focus on subverting underlying technologies and improving efficiency and reducing costs.
Midstream: A technology platform for the design and transformation of biological systems and organisms, with the core technology of path development, focusing on the selection of synthetic routes and technical run-through (such as chassis cell selection and transformation, culture condition optimization, purification method development, etc.), emphasizing the versatility of the technology platform, and potentially having CRO (pharmaceutical R&D contract outsourcing service organization) attributes.
Downstream: Involving the application development and product landing of clothing, food, housing and transportation, the core technology lies in the control of the cost, batch difference and yield rate of large-scale production, emphasizing the focus of the application field, the fine polishing of the product and the commercialization of the volume. Among them, in terms of large-scale production, it has the potential to have the attributes of CDMO (pharmaceutical contract customized R&D and production enterprise).
In addition, synthetic biology end products can be classified into three categories according to the two dimensions of demand and unit value: products with low market demand and high unit value (e.g., innovative drugs), products with medium market demand and unit value (e.g., agriculture, food-related products, fine chemicals), and products with high market demand and low unit value (e.g., bulk chemicals, bioenergy).
Note: There is no clear boundary between midstream and downstream enterprises, and the industry as a whole is still in the early stage of industrial development at this stage, and many biotechnology companies are essentially integrating the layout of midstream and downstream.
Q
What areas will be affected by the development of synthetic biology-related technologies?
A
According to McKinsey's estimates, synthetic biology will have an economic impact of $2 trillion to $4 trillion in the future in four major sectors: materials, chemicals and energy, human health and performance, agriculture, aquaculture and food, and consumer goods and services.
Huaan Securities Research Report said that the biomanufacturing (synthetic biology) industry is the key development direction of the bioeconomy, and in the next 10 years, 35% of petrochemical and coal chemical products will be replaced by biomanufacturing products.
In addition, with the rapid progress of computing, bioinformatics and artificial intelligence, the development of synthetic biology has entered the "fast lane".
Q
What is the market potential of synthetic biology?
A
According to the research report of Huaan Securities, the National Development and Reform Commission previously issued the "14th Five-Year Plan" for the development of the bioeconomy, and the trillion-dollar track of the bioeconomy is about to come out.
According to the "Synthetic Biology: Global Market" report released by BCC Consulting, a U.S. market research company, in 2020, the global market size directly driven by synthetic biology has reached $5.319 billion in 2019, and is expected to reach $18.885 billion in 2024, with a compound annual growth rate of 28.8% from 2019 to 2024.
According to McKinsey & Company, synthetic biology can generate a direct economic impact of $1.8 trillion to $3.6 trillion per year from 2030 to 2040.
According to the "White Paper on China's Synthetic Biology Industry 2024" jointly released by Shanghai Synthetic Biology Innovation Center, Boston Consulting Group and B Capital, the global synthetic biology industry has experienced rapid growth in the past five years, with the market size growing from US$5.3 billion in 2018 to over US$17 billion in 2023, with an average annual growth rate of 27%. The global synthetic biology market is expected to maintain a rapid development momentum in the foreseeable future, growing into a global market with a volume of nearly $50 billion by 2028.
Q
Which relevant targets will benefit?
A
Huaan Securities said that biomanufacturing is the key development direction of the bioeconomy, and the industrialization of biomanufacturing is expected to accelerate in the context of frequent policy implementation.
Upstream industry chain: Shengxiang Biotech, MGI, BGI, Genscript Biotechnology (Hong Kong stocks), etc.;
Midstream and downstream industry chains: Gloria Young, Yiduoli, Blue Biotechnology, Shengquan Group, Cathay Biotechnology, Huaheng Biotechnology, Meihua Biotechnology, Bloomage Biotechnology, Jiabiyou, etc.
Note: The classification of related concept stocks is based on the "China Synthetic Biology Industry White Paper 2024" and institutional research reports.
Editor: Zhang Diange Proofreader: Ya Wenhui
Producer: Zhang Nan Issued by: Sun Hong
戳！